COLL vs. VRNA, PRTA, ELVN, ABCL, IRWD, INVA, MIRM, SAVA, TYRA, and BCYC
Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Verona Pharma (VRNA), Prothena (PRTA), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), Mirum Pharmaceuticals (MIRM), Cassava Sciences (SAVA), Tyra Biosciences (TYRA), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical preparations" industry.
Collegium Pharmaceutical (NASDAQ:COLL) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership.
Collegium Pharmaceutical received 65 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 79.95% of users gave Verona Pharma an outperform vote while only 65.16% of users gave Collegium Pharmaceutical an outperform vote.
Collegium Pharmaceutical has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
85.9% of Verona Pharma shares are owned by institutional investors. 4.0% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 4.8% of Verona Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Collegium Pharmaceutical has a net margin of 16.46% compared to Verona Pharma's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.98% beat Verona Pharma's return on equity.
Collegium Pharmaceutical has higher revenue and earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical presently has a consensus target price of $39.00, suggesting a potential upside of 14.20%. Verona Pharma has a consensus target price of $33.20, suggesting a potential upside of 159.78%. Given Verona Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Verona Pharma is more favorable than Collegium Pharmaceutical.
In the previous week, Verona Pharma had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 8 mentions for Verona Pharma and 7 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.49 beat Verona Pharma's score of 0.13 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.
Summary
Collegium Pharmaceutical beats Verona Pharma on 10 of the 18 factors compared between the two stocks.
Get Collegium Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Collegium Pharmaceutical Competitors List
Related Companies and Tools
